The Prognostic Role of Perioperative Dexamethasone in Aseptic Revision Hip Arthroplasty—A Retrospective Cohort Study
Fuente:
Wiley Open Access
Salvato in:
| Autori principali: | , , , , , , , |
|---|---|
| Natura: | Artículo Open Access |
| Pubblicazione: |
Wiley
2025
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1867014038122135552 |
|---|---|
| author | Qiyu Xie Zhixin Liao Hong Xu Wai Yao Xuming Chen Xufeng Wan Duan Wang Zongke Zhou |
| author_facet | Qiyu Xie Zhixin Liao Hong Xu Wai Yao Xuming Chen Xufeng Wan Duan Wang Zongke Zhou Qiyu Xie Zhixin Liao Hong Xu Wai Yao Xuming Chen Xufeng Wan Duan Wang Zongke Zhou |
| collection | Wiley Open Access |
| contents | The Prognostic Role of Perioperative Dexamethasone in Aseptic Revision Hip Arthroplasty—A Retrospective Cohort Study Qiyu Xie Zhixin Liao Hong Xu Wai Yao Xuming Chen Xufeng Wan Duan Wang Zongke Zhou Orthopaedic Surgery ABSTRACTObjectiveAseptic hip revision arthroplasty often results in significant postoperative pain, inflammation, nausea, and vomiting. While perioperative dexamethasone has demonstrated benefits in primary hip arthroplasty, its efficacy and safety in revision procedures remain unclear. This study aims to evaluate the effects of perioperative dexamethasone on postoperative pain, inflammation, postoperative nausea and vomiting (PONV), and safety in aseptic hip revision.MethodsA retrospective cohort study was conducted on 414 patients undergoing aseptic hip revision arthroplasty between 2008 and 2023. Patients were categorized into two groups: those receiving dexamethasone perioperatively (n = 218) and a control group (n = 196). Outcomes included Visual Analog Scale (VAS) pain scores, inflammation markers including C‐reactive protein (CRP) and interleukin‐6 (IL‐6), PONV incidence, analgesic and antiemetic usage, length of stay (LOS), and postoperative complications. Independent samples t‐test or Mann–Whitney U test is applied to continuous variables based on normality, while chi‐square test or Fisher's exact test is used for categorical variables according to sample size.ResultsThe dexamethasone group (average dose: 12.67 mg) exhibited significantly lower VAS scores (p < 0.001) and reduced morphine use on postoperative days (PODs) 1–3. CRP (POD2: 40.60 mg/L vs. 111.66 mg/L) and IL‐6 levels (POD1: 31.85 pg/mL vs. 138.28 pg/mL) were significantly lower in the dexamethasone group (both p < 0.001). PONV incidence (28.4% vs. 40.81%) and antiemetic usage were reduced in the dexamethasone group. No significant differences were observed in LOS or postoperative complications between the two groups.ConclusionPerioperative low‐dose dexamethasone effectively mitigates pain, inflammation, and PONV in aseptic hip revision arthroplasty without increasing the risk of complications. 10.1111/os.70113 http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| doi_str_mv | 10.1111/os.70113 |
| format | Artículo Open Access |
| id | wiley_oa_10_1111_os_70113 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | The Prognostic Role of Perioperative Dexamethasone in Aseptic Revision Hip Arthroplasty—A Retrospective Cohort Study Qiyu Xie Zhixin Liao Hong Xu Wai Yao Xuming Chen Xufeng Wan Duan Wang Zongke Zhou Orthopaedic Surgery The Prognostic Role of Perioperative Dexamethasone in Aseptic Revision Hip Arthroplasty—A Retrospective Cohort Study Qiyu Xie Zhixin Liao Hong Xu Wai Yao Xuming Chen Xufeng Wan Duan Wang Zongke Zhou Orthopaedic Surgery ABSTRACTObjectiveAseptic hip revision arthroplasty often results in significant postoperative pain, inflammation, nausea, and vomiting. While perioperative dexamethasone has demonstrated benefits in primary hip arthroplasty, its efficacy and safety in revision procedures remain unclear. This study aims to evaluate the effects of perioperative dexamethasone on postoperative pain, inflammation, postoperative nausea and vomiting (PONV), and safety in aseptic hip revision.MethodsA retrospective cohort study was conducted on 414 patients undergoing aseptic hip revision arthroplasty between 2008 and 2023. Patients were categorized into two groups: those receiving dexamethasone perioperatively (n = 218) and a control group (n = 196). Outcomes included Visual Analog Scale (VAS) pain scores, inflammation markers including C‐reactive protein (CRP) and interleukin‐6 (IL‐6), PONV incidence, analgesic and antiemetic usage, length of stay (LOS), and postoperative complications. Independent samples t‐test or Mann–Whitney U test is applied to continuous variables based on normality, while chi‐square test or Fisher's exact test is used for categorical variables according to sample size.ResultsThe dexamethasone group (average dose: 12.67 mg) exhibited significantly lower VAS scores (p < 0.001) and reduced morphine use on postoperative days (PODs) 1–3. CRP (POD2: 40.60 mg/L vs. 111.66 mg/L) and IL‐6 levels (POD1: 31.85 pg/mL vs. 138.28 pg/mL) were significantly lower in the dexamethasone group (both p < 0.001). PONV incidence (28.4% vs. 40.81%) and antiemetic usage were reduced in the dexamethasone group. No significant differences were observed in LOS or postoperative complications between the two groups.ConclusionPerioperative low‐dose dexamethasone effectively mitigates pain, inflammation, and PONV in aseptic hip revision arthroplasty without increasing the risk of complications. 10.1111/os.70113 http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| title | The Prognostic Role of Perioperative Dexamethasone in Aseptic Revision Hip Arthroplasty—A Retrospective Cohort Study |
| topic | Orthopaedic Surgery |
| url | https://onlinelibrary.wiley.com/doi/10.1111/os.70113 |